A. Bron, M. Doğru, J. Horwath-winter, Takashi Kojima, Illés Kovács, W. G. Müller-Lierheim, G. V. van Setten, C. Belmonte
1University of Oxford, Nuffield Laboratory of Ophthalmology, Nuffield Dept of Clinical Neurosciences, OX1 2JD Oxford, UK 2Department of Ophthalmology, Keio University School of Medicine, 160-8582 Tokyo, Japan 3Department of Ophthalmology, Medical University of Graz, 8036 Graz, Austria 4Department of Ophthalmology, Semmelweis University, H-1085 Budapest, Hungary 5i.com medical GmbH, 81241 München, Germany 6St. Erik Eye Hospital and Karolinska Institutet, 17164 Solna, Sweden 7Instituto de Neurociencias UMH-CSIC, 03550 Alicante, Spain *Correspondence: carlos.belmonte@umh.es (Carlos Belmonte) Academic Editor: Graham Pawelec Submitted: 8 March 2022 Accepted: 30 March 2022 Published: 28 April 2022
1牛津大学纳菲尔德眼科实验室，纳菲尔德临床神经科学系，牛津ox12jd，英国2庆应义大学医学院眼科，160-8582东京，日本3格拉茨医科大学眼科，8036格拉茨，奥地利4塞梅尔魏斯大学眼科，H-1085布达佩斯，匈牙利5i.com Medical GmbH, 81241 m nchen，德国6St。7神经科学研究所UMH-CSIC, 03550 Alicante, Spain *通讯:carlos.belmonte@umh.es (Carlos Belmonte)学术编辑:Graham Pawelec提交:2022年3月8日接收:2022年3月30日发布:2022年4月28日
{"title":"Reflections on the Ocular Surface: Summary of the Presentations at the 4th Coronis Foundation Ophthalmic Symposium Debate: \"A Multifactorial Approach to Ocular Surface Disorders\" (August 31 2021).","authors":"A. Bron, M. Doğru, J. Horwath-winter, Takashi Kojima, Illés Kovács, W. G. Müller-Lierheim, G. V. van Setten, C. Belmonte","doi":"10.31083/j.fbl2705142","DOIUrl":"https://doi.org/10.31083/j.fbl2705142","url":null,"abstract":"1University of Oxford, Nuffield Laboratory of Ophthalmology, Nuffield Dept of Clinical Neurosciences, OX1 2JD Oxford, UK 2Department of Ophthalmology, Keio University School of Medicine, 160-8582 Tokyo, Japan 3Department of Ophthalmology, Medical University of Graz, 8036 Graz, Austria 4Department of Ophthalmology, Semmelweis University, H-1085 Budapest, Hungary 5i.com medical GmbH, 81241 München, Germany 6St. Erik Eye Hospital and Karolinska Institutet, 17164 Solna, Sweden 7Instituto de Neurociencias UMH-CSIC, 03550 Alicante, Spain *Correspondence: carlos.belmonte@umh.es (Carlos Belmonte) Academic Editor: Graham Pawelec Submitted: 8 March 2022 Accepted: 30 March 2022 Published: 28 April 2022","PeriodicalId":50430,"journal":{"name":"Frontiers in Bioscience-Landmark","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74115928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Gualdi-Russo, I. Saguto, P. Frisoni, M. Neri, J. Mongillo, N. Rinaldo
BACKGROUND Counting the tooth cementum annulations (TCA) is a method for estimating the age at death of adults by sections of their tooth root. The objective of this study was to assess the precision of counting the cementum incremental lines and the congruence between known age and age estimates. Possible factors affecting the accuracy of the estimate were also analyzed. METHODS A sample of 67 permanent teeth extracted from individuals with known age (18-84 years) and sex was analyzed to calculate the dental age. RESULTS Results demonstrate an excellent inter- and intra-observer reliability of annuli counting, with dissimilarities within the limits of agreement. A moderate positive correlation was found between chronological age and TCA. Our results showed that age congruence rates differed across age groups (85% congruence in individuals ≤30 years; 75% in individuals aged 31-60 years; 60% in the over 60s). Considering the bias, this method showed a clear tendency to underestimate age in specimens from old people. After age 43, the TCA estimate is highly inaccurate exceeding the underestimation of 10 years, on average, in comparison to the chronological age. Both chronological age and dental arch seem to influence the accuracy of estimates, unlike sex and the tooth root number. CONCLUSIONS TCA analysis is characterized by high precision and low accuracy, decreasing with age. Therefore, its applicability is limited in elderly subjects. The choice of methods for age estimation in adult skeletal remains should take into account the particular age range of individuals. We recommend using different age estimation methods to verify the reliability of the performed assessments.
{"title":"Age estimation using tooth cementum annulations: bias and sources of inaccuracy.","authors":"E. Gualdi-Russo, I. Saguto, P. Frisoni, M. Neri, J. Mongillo, N. Rinaldo","doi":"10.31083/j.fbl2705141","DOIUrl":"https://doi.org/10.31083/j.fbl2705141","url":null,"abstract":"BACKGROUND\u0000Counting the tooth cementum annulations (TCA) is a method for estimating the age at death of adults by sections of their tooth root. The objective of this study was to assess the precision of counting the cementum incremental lines and the congruence between known age and age estimates. Possible factors affecting the accuracy of the estimate were also analyzed.\u0000\u0000\u0000METHODS\u0000A sample of 67 permanent teeth extracted from individuals with known age (18-84 years) and sex was analyzed to calculate the dental age.\u0000\u0000\u0000RESULTS\u0000Results demonstrate an excellent inter- and intra-observer reliability of annuli counting, with dissimilarities within the limits of agreement. A moderate positive correlation was found between chronological age and TCA. Our results showed that age congruence rates differed across age groups (85% congruence in individuals ≤30 years; 75% in individuals aged 31-60 years; 60% in the over 60s). Considering the bias, this method showed a clear tendency to underestimate age in specimens from old people. After age 43, the TCA estimate is highly inaccurate exceeding the underestimation of 10 years, on average, in comparison to the chronological age. Both chronological age and dental arch seem to influence the accuracy of estimates, unlike sex and the tooth root number.\u0000\u0000\u0000CONCLUSIONS\u0000TCA analysis is characterized by high precision and low accuracy, decreasing with age. Therefore, its applicability is limited in elderly subjects. The choice of methods for age estimation in adult skeletal remains should take into account the particular age range of individuals. We recommend using different age estimation methods to verify the reliability of the performed assessments.","PeriodicalId":50430,"journal":{"name":"Frontiers in Bioscience-Landmark","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75191543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Gomes, H. Martino, Nikolai Kolba, J‐A. Cheng, Nikita Agarwal, M. M. Rocha, E. Tako
BACKGROUND Biofortification is a method that improves the nutritional value of food crops through conventional plant breeding. The aim of this study was to evaluate the effects of intra-amniotic administration of soluble extracts from zinc (Zn) biofortified and Zn standard cowpea (Vigna unguiculata L. Walp.) flour on intestinal functionality and morphology, inflammation, and gut microbiota, in vivo. METHODS Seven treatment groups were utilized: (1) No Injection; (2) 18 MΩ H2O; (3) 50 mg/mL Inulin; (4) 50 mg/mL BRS Pajeú soluble extract (Zn standard); (5) 50 mg/mL BRS Aracê soluble extract (Zn biofortified); (6) 50 mg/mL BRS Imponente soluble extract (Zn biofortified); (7) 50 mg/mL BRS Xiquexique soluble extract (Zn biofortified). RESULTS Treatment groups with BRS Imponente and BRS Xiquexique reduced the abundance of Clostridium and E. coli when compared with all other experimental groups. All cowpea soluble extracts increased villi goblet cell number (total), specifically acidic goblet cell type number per villi relative to inulin and 18MΩ H2O groups. Moreover, BRS Xiquexique increased the crypt goblet diameter and the crypt depth compared to all treatments and controls. The Zn content in the Zn biofortified cowpea flours was higher when compared to the Zn standard flour (BRS Pajeú), and the phytate: Zn molar ratio was lower in the Zn biofortified flours compared to the Zn standard flour. In general, all cowpea soluble extracts maintained the gene expression of proteins involved with Zn and iron absorption, brush border membrane (BBM) functionality and inflammation compared to inulin and 18MΩ H2O. CONCLUSIONS This study demonstrates the potential nutritional benefit of standard and biofortified cowpea treatment groups to improve intestinal morphology, BBM functionality, inflammation, and gut microbiota, with the highest effect of BRS Xiquexique soluble extracts to improve assessed cecal microflora populations and intestinal morphology.
{"title":"Zinc Biofortified Cowpea (Vigna unguiculata L. Walp.) Soluble Extracts Modulate Assessed Cecal Bacterial Populations and Gut Morphology In Vivo (Gallus gallus).","authors":"M. Gomes, H. Martino, Nikolai Kolba, J‐A. Cheng, Nikita Agarwal, M. M. Rocha, E. Tako","doi":"10.31083/j.fbl2705140","DOIUrl":"https://doi.org/10.31083/j.fbl2705140","url":null,"abstract":"BACKGROUND\u0000Biofortification is a method that improves the nutritional value of food crops through conventional plant breeding. The aim of this study was to evaluate the effects of intra-amniotic administration of soluble extracts from zinc (Zn) biofortified and Zn standard cowpea (Vigna unguiculata L. Walp.) flour on intestinal functionality and morphology, inflammation, and gut microbiota, in vivo.\u0000\u0000\u0000METHODS\u0000Seven treatment groups were utilized: (1) No Injection; (2) 18 MΩ H2O; (3) 50 mg/mL Inulin; (4) 50 mg/mL BRS Pajeú soluble extract (Zn standard); (5) 50 mg/mL BRS Aracê soluble extract (Zn biofortified); (6) 50 mg/mL BRS Imponente soluble extract (Zn biofortified); (7) 50 mg/mL BRS Xiquexique soluble extract (Zn biofortified).\u0000\u0000\u0000RESULTS\u0000Treatment groups with BRS Imponente and BRS Xiquexique reduced the abundance of Clostridium and E. coli when compared with all other experimental groups. All cowpea soluble extracts increased villi goblet cell number (total), specifically acidic goblet cell type number per villi relative to inulin and 18MΩ H2O groups. Moreover, BRS Xiquexique increased the crypt goblet diameter and the crypt depth compared to all treatments and controls. The Zn content in the Zn biofortified cowpea flours was higher when compared to the Zn standard flour (BRS Pajeú), and the phytate: Zn molar ratio was lower in the Zn biofortified flours compared to the Zn standard flour. In general, all cowpea soluble extracts maintained the gene expression of proteins involved with Zn and iron absorption, brush border membrane (BBM) functionality and inflammation compared to inulin and 18MΩ H2O.\u0000\u0000\u0000CONCLUSIONS\u0000This study demonstrates the potential nutritional benefit of standard and biofortified cowpea treatment groups to improve intestinal morphology, BBM functionality, inflammation, and gut microbiota, with the highest effect of BRS Xiquexique soluble extracts to improve assessed cecal microflora populations and intestinal morphology.","PeriodicalId":50430,"journal":{"name":"Frontiers in Bioscience-Landmark","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83056694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PURPOSE To compare the progression of neovascular remodeling and subretinal fibrosis in neovascular age-related macular degeneration (NVAMD) after anti-vascular endothelial growth factor (VEGF) therapy. METHODS Twenty eyes from 20 patients with subretinal fibrosis complicating NVAMD were retrospectively reviewed. All patients complied with at least three consecutive monthly intravitreal treatments and final follow-up visit at 12 months after the initial anti-VEGF treatment of aflibercept or ranibizumab. Using optical coherence tomography angiography (OCTA), the central macular thickness (CMT), microvascular density in the superficial capillary plexus (SCP), deep capillary plexus (DCP), choroidal neovascularization (CNV) lesions, as well as subretinal fibrotic lesions were compared between baseline and final visit. RESULTS The mean number for anti-VEGF injections was 4.40 ± 0.88 during the 12 months of follow-up. There was no significant difference in best-corrected visual acuity (BCVA) and vascular density in SCP and DCP (p > 0.05) between baseline and final follow-up. The CMT decreased from 434.95 ± 87.62 μm at baseline to 365.15 ± 78.92 μm at final visit (p = 0.02). Compared with the baseline, the fine vessels, such as capillary tufts, regressed and the relative density of CNV lesion decreased by 19.12% (p = 0.01), while the relative density of the subretinal fibrosis increased approximately 1.21-fold (p = 0.03) at the final follow-up. CONCLUSIONS The progression of neovascular remodeling and subretinal fibrosis may serve as biomarkers to predict incomplete response to anti-VEGF therapy in patients with NVAMD. Subretinal fibrosis complicating NVAMD remains a major obstacle for the management of NVAMD, and anti-VEGF treatment is a potential therapeutic strategy to target neovascular remodeling and subretinal fibrosis as either an additive or alternative therapeutic approach for NVAMD.
{"title":"Neovascular Remodeling and Subretinal Fibrosis as Biomarkers for Predicting Incomplete Response to Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration.","authors":"Jing Wu, Jingfang Zhang","doi":"10.31083/j.fbl2704135","DOIUrl":"https://doi.org/10.31083/j.fbl2704135","url":null,"abstract":"PURPOSE\u0000To compare the progression of neovascular remodeling and subretinal fibrosis in neovascular age-related macular degeneration (NVAMD) after anti-vascular endothelial growth factor (VEGF) therapy.\u0000\u0000\u0000METHODS\u0000Twenty eyes from 20 patients with subretinal fibrosis complicating NVAMD were retrospectively reviewed. All patients complied with at least three consecutive monthly intravitreal treatments and final follow-up visit at 12 months after the initial anti-VEGF treatment of aflibercept or ranibizumab. Using optical coherence tomography angiography (OCTA), the central macular thickness (CMT), microvascular density in the superficial capillary plexus (SCP), deep capillary plexus (DCP), choroidal neovascularization (CNV) lesions, as well as subretinal fibrotic lesions were compared between baseline and final visit.\u0000\u0000\u0000RESULTS\u0000The mean number for anti-VEGF injections was 4.40 ± 0.88 during the 12 months of follow-up. There was no significant difference in best-corrected visual acuity (BCVA) and vascular density in SCP and DCP (p > 0.05) between baseline and final follow-up. The CMT decreased from 434.95 ± 87.62 μm at baseline to 365.15 ± 78.92 μm at final visit (p = 0.02). Compared with the baseline, the fine vessels, such as capillary tufts, regressed and the relative density of CNV lesion decreased by 19.12% (p = 0.01), while the relative density of the subretinal fibrosis increased approximately 1.21-fold (p = 0.03) at the final follow-up.\u0000\u0000\u0000CONCLUSIONS\u0000The progression of neovascular remodeling and subretinal fibrosis may serve as biomarkers to predict incomplete response to anti-VEGF therapy in patients with NVAMD. Subretinal fibrosis complicating NVAMD remains a major obstacle for the management of NVAMD, and anti-VEGF treatment is a potential therapeutic strategy to target neovascular remodeling and subretinal fibrosis as either an additive or alternative therapeutic approach for NVAMD.","PeriodicalId":50430,"journal":{"name":"Frontiers in Bioscience-Landmark","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81371258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Conventional treatments for ovarian cancer, including debulking cytoreductive surgery combined with carboplatin/paclitaxel-based chemotherapy, are insufficient, as evidenced by the high mortality rate, which ranks first among gynecological tumors. Therefore, there is an urgent need to develop new and effective treatment strategies. Recent evidence has shown that metabolic processes and cell behaviors in ovarian cancer are regulated by intracellular factors as well as metabolites in the tumor microenvironment (TME), which determine occurrence, proliferation, and metastasis. In this review, we describe the comprehensive landscape of metabolic cross-talk between ovarian cancer and its TME with a focus on the following four aspects: (1) intracellular metabolism based on the Warburg effect, (2) metabolism in non-tumor cells in the ovarian TME, (3) metabolic communication between tumor cells and non-tumor cells in the TME, and (4) metabolism-related therapeutic targets and agents for ovarian cancer. The metabolic cross-talk between ovarian cancer and its microenvironment involves a complex network of interactions, and interrupting these interactions by metabolic interventions is a promising therapeutic strategy.
{"title":"Metabolic cross-talk between ovarian cancer and the tumor microenvironment-providing potential targets for cancer therapy.","authors":"Y. Lin, Xiao Liang, Xijie Zhang, Yanghong Ni, Xiaoting Zhou, Xia Zhao","doi":"10.31083/j.fbl2704139","DOIUrl":"https://doi.org/10.31083/j.fbl2704139","url":null,"abstract":"Conventional treatments for ovarian cancer, including debulking cytoreductive surgery combined with carboplatin/paclitaxel-based chemotherapy, are insufficient, as evidenced by the high mortality rate, which ranks first among gynecological tumors. Therefore, there is an urgent need to develop new and effective treatment strategies. Recent evidence has shown that metabolic processes and cell behaviors in ovarian cancer are regulated by intracellular factors as well as metabolites in the tumor microenvironment (TME), which determine occurrence, proliferation, and metastasis. In this review, we describe the comprehensive landscape of metabolic cross-talk between ovarian cancer and its TME with a focus on the following four aspects: (1) intracellular metabolism based on the Warburg effect, (2) metabolism in non-tumor cells in the ovarian TME, (3) metabolic communication between tumor cells and non-tumor cells in the TME, and (4) metabolism-related therapeutic targets and agents for ovarian cancer. The metabolic cross-talk between ovarian cancer and its microenvironment involves a complex network of interactions, and interrupting these interactions by metabolic interventions is a promising therapeutic strategy.","PeriodicalId":50430,"journal":{"name":"Frontiers in Bioscience-Landmark","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87533450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jae Sung Lim, D. Lee, Ju-Hyeon Lim, W. Oh, Jun Tae Park, Sang Chul Park, K. Cho
BACKGROUND Cancer is a representative geriatric disease closely related to senescent cells and cell aging in tissues. Senescent cells that surround cancer tissues reduce the effects of various cancer treatments and induce cancer recurrence through senescence-associated secretory phenotype (SASP) secretion. Thus, for good therapeutic effect, candidate drugs should be selective for both cancer and senescent cells. In this study, we investigated the selective effect of piperine as a potential senostatic agent as well as an anticancer drug. METHODS The effect of piperine on cytotoxicity and cell proliferation was tested by lactate dehydrogenase (LDH) or water-soluble tetrazolium salt (WST) assay. The levels of p16INK4a and p21, mitogen-activated protein kinases (MAPKs), and mammalian target of rapamycin (mTOR) were analyzed by Western blot analysis. The rejuvenation effects of piperine on the senescent cells were investigated by senescence-associated beta-galactosidase (SA-β-Gal) stain, mitochondria membrane potential (MMP) and reactive oxygen species (ROS) levels, and senescence-associated secretory phenotype (SASP) secretion after treatment with piperine in senescent cells. RESULTS While piperine induced high cytotoxicity in various cancer cell lines, it led to proliferating of premature senescent cells similar with nicotinamide (NA), which is known as a rejuvenating drug of senescent cells. Piperine differently affected cancer cells and premature senescent cells due to the different responses of intracellular signaling pathways and also reversed premature senescence phenotypes and modulated SASP secretion in premature senescent cells. CONCLUSIONS From these results, we propose piperine as an effective cancer treatment that can simultaneously induce senostatic effects and the removal of cancer cells, not as an adjuvant to the existing senostatics for cancer treatment.
{"title":"Piperine: An Anticancer and Senostatic Drug.","authors":"Jae Sung Lim, D. Lee, Ju-Hyeon Lim, W. Oh, Jun Tae Park, Sang Chul Park, K. Cho","doi":"10.31083/j.fbl2704137","DOIUrl":"https://doi.org/10.31083/j.fbl2704137","url":null,"abstract":"BACKGROUND\u0000Cancer is a representative geriatric disease closely related to senescent cells and cell aging in tissues. Senescent cells that surround cancer tissues reduce the effects of various cancer treatments and induce cancer recurrence through senescence-associated secretory phenotype (SASP) secretion. Thus, for good therapeutic effect, candidate drugs should be selective for both cancer and senescent cells. In this study, we investigated the selective effect of piperine as a potential senostatic agent as well as an anticancer drug.\u0000\u0000\u0000METHODS\u0000The effect of piperine on cytotoxicity and cell proliferation was tested by lactate dehydrogenase (LDH) or water-soluble tetrazolium salt (WST) assay. The levels of p16INK4a and p21, mitogen-activated protein kinases (MAPKs), and mammalian target of rapamycin (mTOR) were analyzed by Western blot analysis. The rejuvenation effects of piperine on the senescent cells were investigated by senescence-associated beta-galactosidase (SA-β-Gal) stain, mitochondria membrane potential (MMP) and reactive oxygen species (ROS) levels, and senescence-associated secretory phenotype (SASP) secretion after treatment with piperine in senescent cells.\u0000\u0000\u0000RESULTS\u0000While piperine induced high cytotoxicity in various cancer cell lines, it led to proliferating of premature senescent cells similar with nicotinamide (NA), which is known as a rejuvenating drug of senescent cells. Piperine differently affected cancer cells and premature senescent cells due to the different responses of intracellular signaling pathways and also reversed premature senescence phenotypes and modulated SASP secretion in premature senescent cells.\u0000\u0000\u0000CONCLUSIONS\u0000From these results, we propose piperine as an effective cancer treatment that can simultaneously induce senostatic effects and the removal of cancer cells, not as an adjuvant to the existing senostatics for cancer treatment.","PeriodicalId":50430,"journal":{"name":"Frontiers in Bioscience-Landmark","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75484889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alson Loh, Nur Adania Shaibie, Po Qhuan Chan, P. Leong, Sharrada Segeran, B. Tan, S. Wong, R. Koh, S. Chye, K. Voon
BACKGROUND Oncolytic properties had been demonstrated in Mammalian Orthoreovirus (MRV) and Avian Orthorevirus (ARV). Besides MRV and ARV, Pteropine Orthoreovirus (PRV) is also categorized under the genus Orthoreovirus. PRV7S (Sikamat virus) is an orthoreovirus isolated in Malaysia. Present study aims to investigate the oncolytic effects of PRV7S on ranges of nasopharyngeal carcinoma (NPC) cells through apoptosis in comparison to MRV3. METHODS Non-cancerous nasopharyngeal (NCNP) and NPC cells were infected by PRV7S and MRV3. The effects of PRV7S on the proliferation inhibition and apoptotic activity of NPC cells was examined using MTT assay and flow cytometry. Additionally, western blot assay was performed to analyze the expression of RAS and apoptotic protein. Lastly, qPCR assay was performed to demonstrate that PRV7S and MRV3 replicated in infected-NPC and infected-NCNP cells. RESULTS The proliferation of NPC cells were significantly inhibited after PRV7S infection in a time dependent manner in comparison to infected-NCPC cells. Flow cytometry analysis showed that PRV7S infection was able to induce apoptosis on NPC cells at 48 hpi. Western blot results showed that upon PRV7S infection, N/H/K RAS protein expression was reduced, whereas caspase-3 protein expression increased in NPC cells. qPCR assay showed higher viral load of PRV7S found in infected-NPC compared to infected-NCNP cells. CONCLUSIONS PRV7S inhibits the proliferation and induces apoptosis of NPC cells similar to MRV3. Therefore, PRV7S is a potential oncolytic virus.
{"title":"Pteropine Orthoreovirus, PRV7S (Sikamat Virus) Demonstrates Oncolysis in Nasopharyngeal Carcinoma Cell Lines.","authors":"Alson Loh, Nur Adania Shaibie, Po Qhuan Chan, P. Leong, Sharrada Segeran, B. Tan, S. Wong, R. Koh, S. Chye, K. Voon","doi":"10.31083/j.fbl2704138","DOIUrl":"https://doi.org/10.31083/j.fbl2704138","url":null,"abstract":"BACKGROUND\u0000Oncolytic properties had been demonstrated in Mammalian Orthoreovirus (MRV) and Avian Orthorevirus (ARV). Besides MRV and ARV, Pteropine Orthoreovirus (PRV) is also categorized under the genus Orthoreovirus. PRV7S (Sikamat virus) is an orthoreovirus isolated in Malaysia. Present study aims to investigate the oncolytic effects of PRV7S on ranges of nasopharyngeal carcinoma (NPC) cells through apoptosis in comparison to MRV3.\u0000\u0000\u0000METHODS\u0000Non-cancerous nasopharyngeal (NCNP) and NPC cells were infected by PRV7S and MRV3. The effects of PRV7S on the proliferation inhibition and apoptotic activity of NPC cells was examined using MTT assay and flow cytometry. Additionally, western blot assay was performed to analyze the expression of RAS and apoptotic protein. Lastly, qPCR assay was performed to demonstrate that PRV7S and MRV3 replicated in infected-NPC and infected-NCNP cells.\u0000\u0000\u0000RESULTS\u0000The proliferation of NPC cells were significantly inhibited after PRV7S infection in a time dependent manner in comparison to infected-NCPC cells. Flow cytometry analysis showed that PRV7S infection was able to induce apoptosis on NPC cells at 48 hpi. Western blot results showed that upon PRV7S infection, N/H/K RAS protein expression was reduced, whereas caspase-3 protein expression increased in NPC cells. qPCR assay showed higher viral load of PRV7S found in infected-NPC compared to infected-NCNP cells.\u0000\u0000\u0000CONCLUSIONS\u0000PRV7S inhibits the proliferation and induces apoptosis of NPC cells similar to MRV3. Therefore, PRV7S is a potential oncolytic virus.","PeriodicalId":50430,"journal":{"name":"Frontiers in Bioscience-Landmark","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80877753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiaohua Li, Guishuang Ying, Xiaohui Liu, Min Yuan, R. Yin
BACKGROUND Cumulative evidence suggests that the risk of eye tumors varies among different age groups and populations. The purpose of the present study was to assess the age distribution of eye tumors in China. METHODS In this retrospective study, the age distribution of various types of eye tumors was analyzed on surgically excised and histologically confirmed specimens obtained from 4492 patients (4526 eyes), collected between 2001 and 2017. RESULTS Of the 4526 specimens, 3156 eyes (69.7%) had benign eye tumors, while 1370 eyes (30.3%) had malignant tumors. The age-specific incidence of eye tumors was characterized by a bimodal distribution, one peak occurred at age 0-9 years (19.7%) and the other at 50-59 years (14.7%) of age. Malignant eyelid tumors were very rare under the age of 20 years, but increased to 78% of all eyelid tumors by the age of 70 years. Children aged 0-9 years old were 6.5 times as likely to have a malignant eye tumor (95% CI, 4.1-10.4) as those aged 10-19 years. The age-related variation of eye tumors was also observed in the top ten categories of both benign (p < 0.001) and malignant types (p = 0.001). CONCLUSIONS These results showed that age is a major factor determining the type of eye tumor, confirmed by histopathological analysis.
{"title":"Age Distribution of 4526 Surgically Excised Specimens of Eye Tumors by Histopathological Examination in China.","authors":"Xiaohua Li, Guishuang Ying, Xiaohui Liu, Min Yuan, R. Yin","doi":"10.31083/j.fbl2704132","DOIUrl":"https://doi.org/10.31083/j.fbl2704132","url":null,"abstract":"BACKGROUND\u0000Cumulative evidence suggests that the risk of eye tumors varies among different age groups and populations. The purpose of the present study was to assess the age distribution of eye tumors in China.\u0000\u0000\u0000METHODS\u0000In this retrospective study, the age distribution of various types of eye tumors was analyzed on surgically excised and histologically confirmed specimens obtained from 4492 patients (4526 eyes), collected between 2001 and 2017.\u0000\u0000\u0000RESULTS\u0000Of the 4526 specimens, 3156 eyes (69.7%) had benign eye tumors, while 1370 eyes (30.3%) had malignant tumors. The age-specific incidence of eye tumors was characterized by a bimodal distribution, one peak occurred at age 0-9 years (19.7%) and the other at 50-59 years (14.7%) of age. Malignant eyelid tumors were very rare under the age of 20 years, but increased to 78% of all eyelid tumors by the age of 70 years. Children aged 0-9 years old were 6.5 times as likely to have a malignant eye tumor (95% CI, 4.1-10.4) as those aged 10-19 years. The age-related variation of eye tumors was also observed in the top ten categories of both benign (p < 0.001) and malignant types (p = 0.001).\u0000\u0000\u0000CONCLUSIONS\u0000These results showed that age is a major factor determining the type of eye tumor, confirmed by histopathological analysis.","PeriodicalId":50430,"journal":{"name":"Frontiers in Bioscience-Landmark","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89197992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Polyphenols, members of phytochemical superfamily rich in vegetables and fruits, include flavonoids, non-flavonoids, and phenolic acids. Their biological effects includes classical antioxidation (e.g., radical-scavenging, metal chelating, NOX inhibition, attenuation on mitochondrial respiration, inhibition on xanthine oxidase, and upregulations on endogenous antioxidant enzymes), multiple regulations on cell signaling (e.g., AMPK activation, SirT1 activation, eNOS activation, FOXO activation, NFκB inactivation, PI3K/AkT inhibition, mTORC1 inhibition, PKC inhibition, MAPK inhibition, ERK inhibition, JAK/STAT inhibition, IKK/JNK inhibition, PDE inhibition, β-catenin inactivation, downregulation on TLR expression, ACE inhibition, adiponectin elevation, attenuated ET-1 production, and K+ channel activation), and many other actions (e.g., inhibition on α-glucosidase, anticoagulation, γ-secretase inhibition, monoamine oxidase inhibition, LPL upregulation, ANGPTL4 suppression, upregulation on paraoxonase 1, PAI-1 downregulation, tPA upregulation, immunoregulation, epigenetic modulation, and altered gut microbiota). Such multi- targeting and functions exhibiting antioxidative stress and antiinflammation as major pillars along with many other antagonisms could not only afford healthy polyphenols suitable supplements for promoting health, but also advance them to therapeutic applications. This review aims to translate diverse polyphenolic biochemical actions to clinical applications in fighting against non-communicable diseases such as CVD, cancer, diabetes, obesity, neurodegeneration, inflammatory diseases (e.g., IBD, IBS, NAFLD, etc.), AMD, allergy, and autoimmunity as well as communicable infection (e.g., bacteria, fungal, and viral).
{"title":"Quarter-Century Explorations of Bioactive Polyphenols: Diverse Health Benefits.","authors":"Arthur Chu","doi":"10.31083/j.fbl2704134","DOIUrl":"https://doi.org/10.31083/j.fbl2704134","url":null,"abstract":"Polyphenols, members of phytochemical superfamily rich in vegetables and fruits, include flavonoids, non-flavonoids, and phenolic acids. Their biological effects includes classical antioxidation (e.g., radical-scavenging, metal chelating, NOX inhibition, attenuation on mitochondrial respiration, inhibition on xanthine oxidase, and upregulations on endogenous antioxidant enzymes), multiple regulations on cell signaling (e.g., AMPK activation, SirT1 activation, eNOS activation, FOXO activation, NFκB inactivation, PI3K/AkT inhibition, mTORC1 inhibition, PKC inhibition, MAPK inhibition, ERK inhibition, JAK/STAT inhibition, IKK/JNK inhibition, PDE inhibition, β-catenin inactivation, downregulation on TLR expression, ACE inhibition, adiponectin elevation, attenuated ET-1 production, and K+ channel activation), and many other actions (e.g., inhibition on α-glucosidase, anticoagulation, γ-secretase inhibition, monoamine oxidase inhibition, LPL upregulation, ANGPTL4 suppression, upregulation on paraoxonase 1, PAI-1 downregulation, tPA upregulation, immunoregulation, epigenetic modulation, and altered gut microbiota). Such multi- targeting and functions exhibiting antioxidative stress and antiinflammation as major pillars along with many other antagonisms could not only afford healthy polyphenols suitable supplements for promoting health, but also advance them to therapeutic applications. This review aims to translate diverse polyphenolic biochemical actions to clinical applications in fighting against non-communicable diseases such as CVD, cancer, diabetes, obesity, neurodegeneration, inflammatory diseases (e.g., IBD, IBS, NAFLD, etc.), AMD, allergy, and autoimmunity as well as communicable infection (e.g., bacteria, fungal, and viral).","PeriodicalId":50430,"journal":{"name":"Frontiers in Bioscience-Landmark","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85971293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maikerly Reyes, M. Taghvaei, Siyuan Yu, A. Sathe, Sarah Collopy, Giyarpuram N Prashant, James J. Evans, M. Karsy
BACKGROUND The proximity of craniopharyngiomas (CPs) to critical neurovascular structures can lead to a host of neurologic and endocrine complications that lead to difficulty with surgical management. In this review, we examine the molecular and genetic markers implicated in CP, their involvement in tumorigenic pathways, and their impact on CP prognosis and treatment. METHODS We undertook a focused review of relevant articles, clinical trials, and molecular summaries regarding CP. RESULTS Genetic and immunological markers show variable expression in different types of CP. BRAF is implicated in tumorigenesis in papillary CP (pCP), whereas CTNNB1 and EGFR are often overexpressed in adamantinomatous CP (aCP) and VEGF is overexpressed in aCP and recurrent CP. Targeted treatment modalities inhibiting these pathways can shrink or halt progression of CP. In addition, EGFR inhibitors may sensitize tumors to radiation therapy. These drugs show promise in medical management and neoadjuvant therapy for CP. Immunotherapy, including anti-interleukin-6 (IL-6) drugs and interferon treatment, are also effective in managing tumor growth. Ongoing clinical trials in CP are limited but are testing BRAF/MET inhibitors and IL-6 monoclonal antibodies. CONCLUSIONS Genetic and immunological markers show variable expression in different subtypes of CP. Several current molecular treatments have shown some success in the management of this disease. Additional clinical trials and targeted therapies will be important to improve CP patient outcomes.
{"title":"Targeted Therapy in the Management of Modern Craniopharyngiomas.","authors":"Maikerly Reyes, M. Taghvaei, Siyuan Yu, A. Sathe, Sarah Collopy, Giyarpuram N Prashant, James J. Evans, M. Karsy","doi":"10.31083/j.fbl2704136","DOIUrl":"https://doi.org/10.31083/j.fbl2704136","url":null,"abstract":"BACKGROUND\u0000The proximity of craniopharyngiomas (CPs) to critical neurovascular structures can lead to a host of neurologic and endocrine complications that lead to difficulty with surgical management. In this review, we examine the molecular and genetic markers implicated in CP, their involvement in tumorigenic pathways, and their impact on CP prognosis and treatment.\u0000\u0000\u0000METHODS\u0000We undertook a focused review of relevant articles, clinical trials, and molecular summaries regarding CP.\u0000\u0000\u0000RESULTS\u0000Genetic and immunological markers show variable expression in different types of CP. BRAF is implicated in tumorigenesis in papillary CP (pCP), whereas CTNNB1 and EGFR are often overexpressed in adamantinomatous CP (aCP) and VEGF is overexpressed in aCP and recurrent CP. Targeted treatment modalities inhibiting these pathways can shrink or halt progression of CP. In addition, EGFR inhibitors may sensitize tumors to radiation therapy. These drugs show promise in medical management and neoadjuvant therapy for CP. Immunotherapy, including anti-interleukin-6 (IL-6) drugs and interferon treatment, are also effective in managing tumor growth. Ongoing clinical trials in CP are limited but are testing BRAF/MET inhibitors and IL-6 monoclonal antibodies.\u0000\u0000\u0000CONCLUSIONS\u0000Genetic and immunological markers show variable expression in different subtypes of CP. Several current molecular treatments have shown some success in the management of this disease. Additional clinical trials and targeted therapies will be important to improve CP patient outcomes.","PeriodicalId":50430,"journal":{"name":"Frontiers in Bioscience-Landmark","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89174710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：